Peptides: the fat-loss ones are proven. The healing and anti-aging ones haven't been tested yet

Evidence check, September 29, 2026

The claim: "Peptides like BPC-157 heal injuries and epitalon slows aging, the way GLP-1s melt fat."

Our grade: Unproven. GLP-1 peptides for fat loss are Solid, backed by trials in thousands of people. BPC-157 and epitalon work in rats and mice, but no controlled trial in people has reported yet.

Leo is 25. He lifts four days a week, and for two months his right elbow has ached every time he does pull-ups. His feed is full of people calling BPC-157 the "Wolverine peptide". A friend at the gym says it fixed his shoulder in three weeks, and a website will ship Leo a vial tomorrow.

Should he try it?

"Peptides" covers drugs with very different evidence behind them. Some are among the best-tested medicines of the last decade. Others have barely been tried in people. Here is how to tell them apart.

Where the claim came from

On September 28, 2026, Jeff Nippard, a coach and science communicator with millions of subscribers, posted "Peptides Are Insane" [1]. He sorted the peptides people use into three groups: fat loss (the GLP-1 drugs), injury healing (BPC-157) and anti-aging (epitalon). He was careful: he said the fat-loss drugs are backed by big trials, the other two mostly aren't, and he advised against BPC-157 for now.

A peptide is a short chain of amino acids, the building blocks of protein. Insulin is one. Many peptides are hormones that carry messages between organs, which is why some make powerful drugs. Most are injected, because the gut digests them like food.

Clue one: the fat-loss peptides are some of the best-tested drugs there are

Semaglutide (Wegovy, Ozempic) copies GLP-1, a gut hormone that tells your brain you're full. In the STEP 1 trial, 1,961 adults with obesity were randomly assigned to weekly semaglutide or a placebo for 68 weeks [2]. On semaglutide, they lost 14.9% of their weight on average, against 2.4% on placebo. Half lost 15% or more.

Tirzepatide (Zepbound, Mounjaro) copies two gut hormones. In SURMOUNT-1, 2,539 adults took it or a placebo for 72 weeks [3]. On the top dose they lost 20.9%, against 3.1% on placebo. More than half lost at least a fifth of their weight.

Retatrutide copies three hormones. In May 2026, Eli Lilly announced the first big phase 3 results: 2,339 adults, randomized, 80 weeks [4]. People who stayed on the top dose lost 28.3%, about 70 pounds (32 kg). Counting everyone who started, including those who stopped, it was 25.0%, against 3.9% on placebo. Those numbers come from the company; the full paper isn't out yet, and the drug isn't approved.

Some of the weight lost is muscle, roughly a fifth in STEP 1, about what any diet of the same size costs (our check of that). Lifting weights and eating enough protein, about 1.6 grams per kilo of body weight a day, is the best-tested way to keep it.

Nausea is common, and 4.5% to 11.3% quit because of side effects. The trials were in people with obesity or overweight, not lean lifters. Still, about 1 in 8 US adults now take a GLP-1 drug [5]. For fat loss, peptides have earned their reputation.

Clue two: BPC-157 has 36 studies behind it, mostly in rats

BPC-157 is a 15-amino-acid piece of a protein found in stomach juice. A 2025 review found 36 studies from 1993 to 2024 [6]. Most were in rats, and they're impressive: torn tendons, muscles and ligaments healed faster, and new blood vessels grew into the injured area.

In people, there are three small studies, all from one clinic in Florida:

• 17 people with knee pain who got BPC-157 injections. Staff phoned them 6 to 12 months later; 14 of the 16 they reached said the pain was better [7]. No comparison group, and some also got another peptide.
• 12 women with a painful bladder condition (interstitial cystitis) who got one injection into the bladder. 10 said their symptoms went away [8]. No comparison group.
• 2 adults who got BPC-157 by IV to check safety. Neither had side effects or changes in blood tests [9].

That's 31 people. Without a comparison group, there's no way to tell the drug's effect from time, rest or hope; this kind of pain often gets better on its own. The review's authors found no clinical safety data, and noted that BPC-157 bought online is unregulated and may not contain what the label says [6].

The rules are shifting. In July 2026, an FDA advisory panel voted 8 to 6 to let compounding pharmacies (pharmacies that mix drugs to order) make BPC-157 [10]. The FDA's own scientists had advised against it, citing too little safety data, and the FDA hasn't decided yet. BPC-157 has been banned in sport since 2022 [11].

The hopeful part: the first real test is under way. A randomized, placebo-controlled trial is giving 120 athletes with a torn hamstring either BPC-157 or a dummy injection for 14 days, and measuring how fast they return to sport [12]. It started in February 2026, and its main results are due in 2027.

So back to Leo. BPC-157 might help his elbow. Nobody knows yet, because it has never been tested against a placebo in people. Within a year or so, there should be a real answer.

Clue three: epitalon's human evidence used a different product

Epitalon is a 4-amino-acid peptide first made in Russia, modeled on an extract of the pineal gland, a small gland in the brain. Its selling point is telomerase, the enzyme that rebuilds telomeres, the caps on your chromosomes that shorten as cells age. In human cells in a dish, epitalon switched telomerase on and the telomeres got longer [13].

In female mice injected from young adulthood until death, average lifespan didn't change [14]. The longest-lived tenth lived 13% longer, and one blood cancer was rarer, but the total number of tumors didn't change.

The human studies came from the same group of researchers in Russia and Ukraine, and they used epithalamin, the gland extract, not the synthetic epitalon sold online. In one, 266 older people got epithalamin, another extract, or both for 2 to 3 years, and were followed for 6 to 8 years; deaths were 1.6 to 1.8 times lower with epithalamin [15]. In another, 70 older people with heart disease were randomly assigned to epithalamin or saline injections for 3 years; after 12 years, 78% of the epithalamin group was alive, against 56% of the controls [16]. That's a big difference, but in a small study that no one outside the group has repeated.

Nippard raised one more concern: most cancers switch telomerase on, so turning it up may not be safe. In mice, epitalon didn't raise tumor rates [14]. In people, no one has checked.

Our grade

The case for the other side: dozens of animal studies agree that BPC-157 speeds healing, and most of the 31 people who got it felt better. The epithalamin trials had control groups and found fewer deaths. Many standard drugs started with results like these.

The case against: animal healing results often fail in people. Uncontrolled reports of pain relief can't separate a drug from time and expectation. Nobody knows what dose is safe to inject for months.

What would change the grade: if the hamstring trial shows faster return to sport on BPC-157 than on placebo, BPC-157 moves to Promising. For epitalon, a randomized trial of the synthetic peptide by an independent group, measuring health or survival and not just telomeres.

What this means for you

• If you have obesity, or overweight with a related health problem, GLP-1 drugs are one of the best-proven options there are. Talk to your doctor, and get them through a pharmacy, not a website selling "research peptides".
• On a GLP-1, lift weights two or three times a week and eat about 1.6 g of protein per kilo a day (about 0.7 g per pound) to keep your muscle. See how to keep muscle on GLP-1 drugs.
• For a nagging tendon like Leo's elbow, the proven fix is loading it: slow, heavy exercises for that tendon, cutting back on what flares it, and patience. Tendon pain often takes 6 to 12 weeks to settle. A physical therapist can set up the exercises.
• If you're thinking about BPC-157 anyway, know that no one knows a safe long-term dose and online vials are unregulated. In a tested sport, it's banned.
• For longer life, the things with human evidence are still exercise, strength, sleep and not smoking. Epitalon isn't one of them yet.

What's next

This starts our Peptides series. The BPC-157 hamstring trial's main results are due in 2027, and the FDA still has to decide on the panel's vote; we'll update this page when either happens. Our next evidence check is hormone therapy for menopause. Related: how much protein you need at your age and testosterone therapy for men.

Sources

1. Nippard J. Peptides Are Insane. YouTube, September 28, 2026. https://www.youtube.com/watch?v=H6SiAe-VObA
2. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med, 2021. 1,961 adults, randomized, double-blind, placebo-controlled, 68 weeks. Funded by Novo Nordisk. https://doi.org/10.1056/NEJMoa2032183
3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med, 2022. 2,539 adults, randomized, double-blind, placebo-controlled, 72 weeks. Funded by Eli Lilly. https://doi.org/10.1056/NEJMoa2206038
4. Eli Lilly. Lilly's triple agonist retatrutide delivered powerful weight loss in TRIUMPH-1. Press release, 2026. 2,339 adults, randomized, double-blind, placebo-controlled, 80 weeks (NCT05929066); not yet published in a journal. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss
5. KFF. Poll: 1 in 8 adults say they are currently taking a GLP-1 drug. November 14, 2025. Survey of 1,350 US adults. https://www.kff.org/public-opinion/poll-1-in-8-adults-say-they-are-currently-taking-a-glp-1-drug-for-weight-loss-diabetes-or-another-condition-even-as-half-say-the-drugs-are-difficult-to-afford/
6. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J, 2025. 36 studies (1993–2024), mostly animal. https://doi.org/10.1177/15563316251355551
7. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med, 2021. 17 patients, retrospective, no control group. https://pubmed.ncbi.nlm.nih.gov/34324435/
8. Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med, 2024. 12 women, single injection, no control group. https://pubmed.ncbi.nlm.nih.gov/39325560/
9. Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med, 2025. 2 adults, no control group. https://pubmed.ncbi.nlm.nih.gov/40131143/
10. McDermott Will & Schulte. Bulk-list bound? PCAC backs majority of peptides in two-day public meeting. July 28, 2026. https://www.mcdermottlaw.com/insights/bulk-list-bound-pcac-backs-majority-of-peptides-in-two-day-public-meeting
11. World Anti-Doping Agency. WADA's 2022 Prohibited List now in force. https://www.wada-ama.org/en/news/wadas-2022-prohibited-list-now-force
12. Hudson Biotech. BPC 157 for acute hamstring muscle strain repair (BPC-HAMSTR). ClinicalTrials.gov NCT07437547. Phase 2, randomized, double-blind, placebo-controlled, 120 people planned, 14 days of treatment. https://clinicaltrials.gov/study/NCT07437547
13. Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med, 2003. Lab study, human fetal cells. https://doi.org/10.1023/a:1025493705728
14. Anisimov VN, Khavinson VKh, Popovich IG, et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology, 2003. Mice, 54 per group, lifelong. https://doi.org/10.1023/a:1025114230714
15. Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett, 2003. 266 older adults, 6 to 8 years. https://pubmed.ncbi.nlm.nih.gov/14523363/
16. Korkushko OV, Khavinson VKh, Shatilo VB, Antonyuk-Shcheglova IA. Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging. Bull Exp Biol Med, 2006. 70 older adults with heart disease, randomized, saline control, 3 years of treatment, 12 years of follow-up. https://doi.org/10.1007/s10517-006-0365-z